Frequently asked questions
The global Cell & Gene Therapy Clinical Trials Market was valued at USD 8354.9 Million in 2022.
The Cell & Gene Therapy Clinical Trials Market is expected to grow at a CAGR of 15.30% between 2023 and 2030, reaching USD 26096.1 Million in 2030.
The phase II category dominated the global market in 2022, accounting for more than 53% of total revenue, as the majority of cell and gene therapies are in this stage of the clinical trial
Adult Patients are the sector with the biggest market demand in the Cell & Gene Therapy Clinical Trials Market
Randomized Controlled Trials (RCTs) sector has a higher Compound Annual Growth Rate (CAGR)
In 2022, North America holds a considerable portion of the Cell & Gene Therapy Clinical Trials Market, accounting for over 48% of the market.
The top players include IQVIA; ICON Plc; Charles River Laboratories International, Inc.; PAREXEL International Corp.; Laboratory Corporation of America Holdings; Syneos Health; Novotech; Medpace, Holdings, Inc.; PPD Inc.; Veristat, LLC, and others.
The primary drivers of the market include rising private and public investments, an increase in the prevalence of cardiovascular illness, and advancements in gene editing and cell therapy technologies.
Stringent regulatory requirements, high research and development expenditures, and limited scalability and production constraints
The market’s significant opportunities include expanding applications in numerous therapeutic areas, rising demand for personalized medicine, and the potential for international collaborations and partnerships.